{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:32:42Z","timestamp":1786116762786,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10620-026-09774-0","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T04:15:15Z","timestamp":1771992915000},"page":"3086-3094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nationwide Trends in Gastrointestinal Bleeding Mortality Before and After the Widespread Adoption of Direct Oral Anticoagulants in the United States, 2007\u20132020"],"prefix":"10.1007","volume":"71","author":[{"given":"Muhammad Haris","family":"Latif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahee","family":"Amedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoha","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"9774_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2015.03.001","volume":"135","author":"JL Mega","year":"2015","unstructured":"Mega JL, Simon T. Overview of the new oral anticoagulants: opportunities and challenges. Thromb Res. 2015;135:1\u201310. https:\/\/doi.org\/10.1016\/j.thromres.2015.03.001.","journal-title":"Thromb Res."},{"key":"9774_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40256-024-00638-4","volume":"24","author":"OS Alkhezi","year":"2024","unstructured":"Alkhezi OS, Buckley LF, Fanikos J. Trends in oral anticoagulant use and individual expenditures across the United States from 2014 to 2020. Am J Cardiovasc Drugs. 2024;24:433\u2013444. https:\/\/doi.org\/10.1007\/s40256-024-00638-4.","journal-title":"Am J Cardiovasc Drugs."},{"key":"9774_CR3","doi-asserted-by":"publisher","first-page":"1049283","DOI":"10.3389\/fphar.2022.1049283","volume":"13","author":"X Chen","year":"2023","unstructured":"Chen X, Wang L, Li H, Huang W, Zhao L, Guo W. Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: an updated traditional and Bayesian network meta-analysis. Front Pharmacol. 2023;13:1049283. https:\/\/doi.org\/10.3389\/fphar.2022.1049283.","journal-title":"Front Pharmacol."},{"key":"9774_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1161\/CIRCULATIONAHA.118.035019","volume":"138","author":"DJ Graham","year":"2018","unstructured":"Graham DJ, Reichman ME, Wernecke M et al. Real-world comparison of bleeding risks among nonvalvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. Circulation. 2018;138:1183\u20131192. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035019.","journal-title":"Circulation."},{"key":"9774_CR5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.5009\/gnl230406","volume":"18","author":"JM Cha","year":"2024","unstructured":"Cha JM, Kim M, Jo HH et al. Real-world risk of gastrointestinal bleeding for direct oral anticoagulants and warfarin users: a distributed network analysis using a common data model. Gut Liver. 2024;18:814\u2013823. https:\/\/doi.org\/10.5009\/gnl230406.","journal-title":"Gut Liver."},{"key":"9774_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13643-022-02146-5","volume":"11","author":"NLJ Chornenki","year":"2022","unstructured":"Chornenki NLJ, Tritschler T, Stucki F et al. All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a protocol for a systematic review and meta-analysis. Syst Rev. 2022;11:269. https:\/\/doi.org\/10.1186\/s13643-022-02146-5.","journal-title":"Syst Rev."},{"key":"9774_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4274\/anatoljmed.2025.38257","volume":"35","author":"O Sorgun","year":"2025","unstructured":"Sorgun O, Ocak NY. Comparison of short-term outcomes in anticoagulated patients with GI bleeding: warfarin versus NOACs. Anatol J Gen Med Res. 2025;35:223\u2013229. https:\/\/doi.org\/10.4274\/anatoljmed.2025.38257.","journal-title":"Anatol J Gen Med Res."},{"key":"9774_CR8","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999\u20132020 on CDC WONDER Online Database. Released 2023. https:\/\/wonder.cdc.gov\/mcd.html"},{"key":"9774_CR9","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Age Adjustment Using the 2000 Projected U.S. Population. Hyattsville: US Department of Health and Human Services, CDC; 2013. https:\/\/www.cdc.gov\/nchs\/data\/statnt\/statnt20.pdf"},{"key":"9774_CR10","first-page":"1","volume":"47","author":"RN Anderson","year":"1998","unstructured":"Anderson RN, Rosenberg HM. Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep. 1998;47:1\u201316.","journal-title":"Natl Vital Stat Rep."},{"key":"9774_CR11","unstructured":"Centers for Medicare & Medicaid Services. Medicare Part D Prescriber Public Use File (PUF) Data. Baltimore: Centers for Medicare & Medicaid Services; 2023. https:\/\/data.cms.gov\/provider-summary-by-type-of-service\/medicare-part-d-prescribers"},{"key":"9774_CR12","doi-asserted-by":"publisher","first-page":"e0191727","DOI":"10.1371\/journal.pone.0191727","volume":"13","author":"PD Ziakas","year":"2018","unstructured":"Ziakas PD, Poulou LS, Gavriilaki E, Zintzaras E. Medicare Part D prescribing for direct oral anticoagulants in the United States: cost, use, and the \u201crubber effect.\u201d PLoS One. 2018;13:e0191727. https:\/\/doi.org\/10.1371\/journal.pone.0191727.","journal-title":"PLoS One."},{"key":"9774_CR13","doi-asserted-by":"publisher","first-page":"e2135691","DOI":"10.1001\/jamanetworkopen.2021.35691","volume":"4","author":"KM Wheelock","year":"2021","unstructured":"Wheelock KM, Wu JM, Khera R et al. Clinician trends in prescribing direct oral anticoagulants for US Medicare beneficiaries (2013\u20132018). JAMA Netw Open. 2021;4:e2135691. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.35691.","journal-title":"JAMA Netw Open."},{"key":"9774_CR14","doi-asserted-by":"publisher","first-page":"e211693","DOI":"10.1001\/jamahealthforum.2021.1693","volume":"2","author":"A Troy","year":"2021","unstructured":"Troy A, Jiang Y, Wirtz HS et al. National trends in use of and spending on oral anticoagulants among US Medicare beneficiaries from 2011 to 2019. JAMA Health Forum. 2021;2:e211693. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.1693.","journal-title":"JAMA Health Forum."},{"key":"9774_CR15","unstructured":"National Library of Medicine. RxNorm: Standardized Nomenclature for Clinical Drugs. Bethesda: National Center for Biomedical Ontology; 2024. Accessed [Month Year]. https:\/\/www.nlm.nih.gov\/research\/umls\/rxnorm"},{"key":"9774_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","volume":"27","author":"AK Wagner","year":"2002","unstructured":"Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299\u2013309. https:\/\/doi.org\/10.1046\/j.1365-2710.2002.00430.x.","journal-title":"J Clin Pharm Ther."},{"key":"9774_CR17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ije\/dyw098","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46:348\u2013355. https:\/\/doi.org\/10.1093\/ije\/dyw098.","journal-title":"Int J Epidemiol."},{"key":"9774_CR18","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u2013891. https:\/\/doi.org\/10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med."},{"key":"9774_CR19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med."},{"key":"9774_CR20","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0.","journal-title":"Lancet."},{"key":"9774_CR21","doi-asserted-by":"publisher","first-page":"h1857","DOI":"10.1136\/bmj.h1857","volume":"350","author":"D Caldeira","year":"2015","unstructured":"Caldeira D, Barra M, Santos AT et al. Risk of gastrointestinal bleeding with non\u2013vitamin K antagonist oral anticoagulants: systematic review and network meta-analysis. BMJ. 2015;350:h1857. https:\/\/doi.org\/10.1136\/bmj.h1857.","journal-title":"BMJ."},{"key":"9774_CR22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1053\/j.gastro.2015.05.002","volume":"149","author":"EW Chan","year":"2015","unstructured":"Chan EW, Lau WC, Leung WK et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149:586\u2013595. https:\/\/doi.org\/10.1053\/j.gastro.2015.05.002.","journal-title":"Gastroenterology."},{"key":"9774_CR23","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1160\/TH16-10-0793","volume":"117","author":"XS Li","year":"2017","unstructured":"Li XS, Deitelzweig S, Keshishian A et al. Effectiveness and safety of apixaban versus warfarin in nonvalvular atrial fibrillation patients in \u201creal-world\u201d clinical practice: a propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117:1072\u20131082. https:\/\/doi.org\/10.1160\/TH16-10-0793.","journal-title":"Thromb Haemost."},{"key":"9774_CR24","doi-asserted-by":"publisher","first-page":"e015981","DOI":"10.1161\/JAHA.119.015981","volume":"9","author":"CI Coleman","year":"2020","unstructured":"Coleman CI, Antz M, Bowrin K et al. Real-world evidence of stroke prevention in atrial fibrillation with direct oral anticoagulants versus warfarin: a meta-analysis. J Am Heart Assoc. 2020;9:e015981. https:\/\/doi.org\/10.1161\/JAHA.119.015981.","journal-title":"J Am Heart Assoc."},{"key":"9774_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","volume":"131","author":"DJ Graham","year":"2015","unstructured":"Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin: a retrospective cohort study. Circulation. 2015;131:157\u2013164. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.012061.","journal-title":"Circulation."},{"key":"9774_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/j.gastro.2023.01.038","volume":"165","author":"WA Ray","year":"2023","unstructured":"Ray WA, Chung CP, Murray KT et al. Association of proton pump inhibitors with reduced risk of upper gastrointestinal bleeding in patients taking direct oral anticoagulants. Gastroenterology. 2023;165:91-102.e7. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.038.","journal-title":"Gastroenterology."},{"key":"9774_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, van Ryn J et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511\u2013520. https:\/\/doi.org\/10.1056\/NEJMoa1502000.","journal-title":"N Engl J Med."},{"key":"9774_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJ Jr, Eikelboom JW et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131\u20131141. https:\/\/doi.org\/10.1056\/NEJMoa1607887.","journal-title":"N Engl J Med."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09774-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09774-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09774-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:53:36Z","timestamp":1786017216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09774-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["9774"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09774-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7650997\/v1","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was based exclusively on publicly available, de-identified data from the Centers for Disease Control and Prevention (CDC WONDER) and the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use Files. As such, it did not involve human participants, identifiable private information, or intervention, and therefore did not require Institutional Review Board (IRB) approval or informed consent in accordance with the U.S. Department of Health and Human Services regulations (45 CFR \u00a746.104[d][4]).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript is an original work that has not been published or submitted elsewhere. All authors have reviewed the final version of the manuscript and agree with its content and submission. The authors affirm that they hold all necessary rights to the data and materials presented, which are derived from open-access government databases and are used in compliance with their respective public data-use terms.","order":3,"name":"Ethics","label":"Rights and permissions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}